Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a
The outbreak of the new coronavirus disease 2019 (COVID-19) has spread rapidly worldwide. Until now, no definite effective treatment has been identified. We reported 3 patients with severe COVID-19 treated with pegylated interferon alfa 2a with satisfactory recovery. Based on these observations, ran...
Main Authors: | Rania M. El-Lababidi, Mohamad Mooty, Maria-Fernanda Bonilla, Nouran M. Salem |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-01-01
|
Series: | IDCases |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2214250920301451 |
Similar Items
-
Early virologic response to сеpeginterferon alfa-2b in combination with ribavirin in treatment of patients with chronic hepatitis C
by: O. O. Znoyko, et al.
Published: (2014-09-01) -
Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers
by: Marisa Boff Costa, et al.
Published: (2018-01-01) -
Five-year follow-up of patients with chronic C hepatitis and sustained virological response Seguimiento a 5 años de pacientes con hepatitis crónica C y respuesta viral sostenida
by: I. Puig-del-Castillo, et al.
Published: (2011-02-01) -
Psoriasis induced by Interferon alfa-2a and ribavirin in a patient followed for hepatitis C
by: N. Amraoui, et al.
Published: (2015-07-01) -
Sustained virological response to treatment of chronic hepatitis C with peginterferon alfa and ribavirin
by: Junior André da Rosa, et al.
Published: (2012-06-01)